Purple Biotech (PPBT) prices up to $18M ADS and warrant offering

Rhea-AI Filing Summary

Purple Biotech Ltd. filed a Form 6-K as a foreign private issuer, furnishing documents related to a planned financing. The exhibits include forms of a pre-funded warrant, a standard warrant, a placement agent warrant, and a securities purchase agreement, along with a press release titled “Purple Biotech Announces Pricing of Up To $18 Million Public Offering.” This indicates the company has set terms for a public offering involving ADSs and warrants.

The company states that this report does not itself constitute an offer to sell or solicit purchases of ADSs or warrants in any jurisdiction where such actions would be unlawful. The Form 6-K and its exhibits are also incorporated by reference into multiple existing Purple Biotech registration statements on Forms S-8, F-1, and F-3, making these offering documents part of those shelves and employee plan registrations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 09/05/2025 - 12:43 PM Learn about SEC filing dates

FAQ

What did Purple Biotech (PPBT) disclose in this Form 6-K?

Purple Biotech Ltd. furnished a Form 6-K that attaches forms of a pre-funded warrant, a warrant, a placement agent warrant, a securities purchase agreement, and a press release titled “Purple Biotech Announces Pricing of Up To $18 Million Public Offering.”

What is the size of the Purple Biotech public offering mentioned?

The attached press release is titled “Purple Biotech Announces Pricing of Up To $18 Million Public Offering,” indicating a public offering of up to $18 million in securities.

What types of securities are involved in Purple Biotechs offering?

The Form 6-K refers to ADSs and warrants, and includes as exhibits a form of pre-funded warrant, a form of warrant, and a form of placement agent warrant, together with a securities purchase agreement.

Does this Purple Biotech Form 6-K itself constitute an offer to sell securities?

No. The company states that the Form 6-K does not constitute an offer to sell or the solicitation of an offer to buy ADSs or warrants in any jurisdiction where such actions would be unlawful before proper registration or qualification.

How does this Form 6-K interact with Purple Biotechs existing registration statements?

The Form 6-K, including all attached exhibits, is incorporated by reference into multiple existing Purple Biotech registration statements on Forms S-8, F-1, and F-3, making these materials part of those registrations from the date of submission.

Who signed this Purple Biotech Form 6-K?

The Form 6-K was signed on behalf of Purple Biotech Ltd. by Gil Efron, the companys Chief Executive Officer.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of September 2025

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

Form 20-F ☒    Form 40-F ☐

Attached hereto and incorporated by reference herein are the following exhibits:

Exhibit No.		Exhibit
4.1		Form of Pre-Funded Warrant
4.2		Form of Warrant
4.3		Form of Placement Agent Warrant
10.1		Form of Securities Purchase Agreement.
99.1		Press Release: Purple Biotech Announces Pricing of Up To $18 Million Public Offering

This Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of ADSs or warrants in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Incorporation by Reference

This Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission on December 27, 2019 (Registration file number 333-235729), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration file number 333-268710), the Registrant’s Registration Statement on Form F-1, as amended, originally filed with the Securities and Exchange Commission on October 30, 2023 (Registration file number 333-275216) and the Registrant’s Registration Statement on Form F-1, filed with the Securities and Exchange Commission on July 22, 2024 (Registration file number 333-280947), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

September 5, 2025	PURPLE BIOTECH LTD.
	By:	/s/ Gil Efron
		Gil Efron
		Chief Executive Officer

2